Educational CME Accredited Programme

Tuesday 28 May 12:30 - 13:30

The Omega-3 tale: Where do we stand?

Chair:
  • Henry Ginsberg, USA
  • Marja-Riitta Taskinen, Finland
  • Omega 3 fatty acids: biological functions

    Alexandros Tselepis, Ioannina, Greece

  • Omega 3 and CV benefit a review of the clinical trials

    Aldo Pietro Maggioni, Florence, Italy

  • REDUCE-IT: an in depth analysis

    Christy Ballantyne, Houston, USA

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Tuesday 28 May 13:45 - 14:45

New approaches to LDL lowering

Chair:
  • Jan Borén, Sweden
  • Alberico L. Catapano, Italy
  • The genetic evidence for inhibiting the cholesterol synthesis pathway to control LDL cholesterol

    Brian Ference, Cambridge, UK

  • Pharmacology of Bempedoic Acid

    Giuseppe Danilo  Norata, Milano, Italy

  • Clinical experience with Bempedoic Acid

    Christy Ballantyne, Houston, USA

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Tuesday 28 May 12:30 - 14:00

PCSK9 inhibition: New insights from clinical trials

Chair:
  • Lale Tokgözoglu, Turkey
  • J. Wouter Jukema, The Netherlands
  • How good are we in reaching the goals?

    Guy de Backer, Gent, Belgium

  • PCSK9 inhibition in clinical practice

    Francois Mach, Geneva, Switzerland

  • A deep look to the results of ODYSSEY outcomes

    J. Wouter Jukema, Leiden, The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Monday 27 May 13:15 - 14:45

Moving from high-intensity statin therapy to high-intensity lipid lowering therapy. Is it time to reconsider the guidelines?

Chair:
  • Paolo Parini, Sweden
  • Olov Wiklund, Sweden
  • Current evidence for LDL causality; goals and targets

    Chris Packard, Glasgow, UK

  • Reality check: Can we get to guideline recommended targets?

    Kornelia  Kotseva, London, UK

  • What is the evidence for upfront combination?

    Michel Farnier, Dijon, France

  • Translation Genetic Data Into Clinical Trial Design

    Kees Hovingh, , The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Monday 27 May 13:15 - 14:15

Problems and solutions in lipid lowering therapy: how to optimise dyslipidaemia management

Chair:
  • Maciej Banach, Poland
  • Ruth Frikke-Schmidt, Denmark
  • The criticality of LDL goal attainment

    Maciej Banach, Lodz, Poland

  • Optimising cholesterol lowering treatment: How many times do we learn the same lesson?

    Luis Masana, Barcelona, Spain

  • Complex cases in lipid lowering treatment: One simple high intensity cholesterol lowering approach fits them all

    Arman Shnork Postadzhiyan, Sofia, Bulgaria

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Sunday 26 May 16:00 - 17:30

How can we improve outcomes in our patients with CAD?

Chair:
  • Christy Ballantyne, USA
  • Christoph Binder, Austria
  • What is the price to pay if we are not at goal?

    Alberto Zambon, Padua, Italy

  • Optimal lipid lowering therapy: New and established therapies

    Christy Ballantyne, Houston, USA

  • Physician-patient relationship: Challenges and opportunities

    Lale Tokgözoglu, Ankara, Turkey

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Sunday 26 May 12:30 - 14:00

PCSK9 Beyond LDL cholesterol

Chair:
  • Jan Borén, Sweden
  • Alberico L. Catapano, Italy
  • PCSK9 In the liver

    Jay Horton, Dallas, USA

  • PCSK9 as a target: Other effects beyond LDL in humans

    Ulf Landmesser, Berlin, Germany

  • PCSK9 and other systems

    Bertrand Cariou, Nantes, France


Sunday 26 May 14:15 - 15:45

Nutritional and dietary approaches for personalised treatment

Chair:
  • M. John Chapman, France
  • Alberto Mello e Silva, Portugal
  • Different approaches to LDL lowering: An overview of options including nutrition, food supplements, and drug therapy

    M. John Chapman, Paris, France

  • Possibilities for nutrigenetics and nutraceuticals in CVD prevention

    Jogchum Plat, Maastricht, The Netherlands

  • Efficacy & Safety of nutraceuticals

    Maciej Banach, Lodz, Poland

  • Panel discussion: When & how to use nutraceuticals in primary prevention

    M. John Chapman, Paris, France

    Maciej Banach, Lodz, Poland

    Alberto Mello e Silva, , Portugal

    Jogchum Plat, Maastricht, The Netherlands

    Margus Viigimaa, Tallinn, Estonia

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Monday 27 May 13:15 - 14:45

Angiopoietin-like proteins, new players in lipid metabolism

Chair:
  • Christy Ballantyne, USA
  • Christoph Binder, Austria
  • What are the Angiopoietin-like proteins, new players in lipid metabolism

    Marcello Arca, Rome, Italy

  • What has Human Genetics taught us about ANGPTL 3, 4 and 8 in lipid metabolism?

    Brian Ference, Cambridge, UK

  • ANGPTL3 as a therapeutic target

    Daniel Gaudet, Montreal, Canada

  • Future direction – Round Table

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Tuesday 28 May 12:30 - 13:30

Familial Chylomicronaemia Syndrome: From Biology To Therapeutic Approaches

Chair:
  • Erik Bruckert, France
  • Daniel Gaudet, Canada
  • The Metabolic basis of Fcs

    Stefano Romeo, Gothenburg, Sweden

  • The Clinical Consequences of Fcs

    Daniel Gaudet, Montreal, Canada

  • Novel Therapeutic Approaches

    Erik S. Stroes, Amsterdam, The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.